Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints.

IF 4.4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2025-08-28 eCollection Date: 2025-07-01 DOI:10.1002/dad2.70176

Alisa Bannerjee, Wendy Elkins, Susan M Resnick, Murat Bilgel

{"title":"Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints.","authors":"Alisa Bannerjee, Wendy Elkins, Susan M Resnick, Murat Bilgel","doi":"10.1002/dad2.70176","DOIUrl":null,"url":null,"abstract":"Introduction: Subjective cognitive complaints often precede declines in objective measures of cognitive performance. Associations of incipient Alzheimer's disease (AD) neuropathology with subjective cognitive complaints may be detectable earlier than associations with neuropsychological testing among cognitively normal individuals.Methods: We examined the independent associations of positron emission tomography measures of amyloid beta and tau pathologies with longitudinal subjective complaints and memory among 91 cognitively normal Baltimore Longitudinal Study of Aging participants using linear mixed effects models. Subjective complaints and memory performance were assessed with the Cognitive Failures Questionnaire and the California Verbal Learning Test, respectively.Results: Greater parahippocampal tau, independent of amyloid, was associated with higher subjective complaints (estimate = 0.25, standard error [SE] = 0.1, P = <math> <mrow><mrow><mspace></mspace> <mn>0.015</mn></mrow> </mrow> </math> ), while greater entorhinal tau corresponded to an attenuated increase in complaints over time (estimate = -0.06, SE = 0.03, P = <math> <mrow><mrow><mspace></mspace> <mn>0.047</mn></mrow> </mrow> </math> ). Hippocampal tau was associated with steeper memory decline (estimate = -0.03, SE = 0.01, P = <math> <mrow><mrow><mspace></mspace> <mn>0.040</mn></mrow> </mrow> </math> ).Conclusion: Subjective cognitive complaints may be a reflection of early cerebral tau pathology in cognitively normal individuals.Highlights: Greater parahippocampal tau was linked with higher subjective cognitive complaints.Entorhinal tau was associated with slower increases in cognitive complaints over time.Subjective complaints may reflect early amyloid and tau in cognitively normal adults.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70176"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394183/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Subjective cognitive complaints often precede declines in objective measures of cognitive performance. Associations of incipient Alzheimer's disease (AD) neuropathology with subjective cognitive complaints may be detectable earlier than associations with neuropsychological testing among cognitively normal individuals.

Methods: We examined the independent associations of positron emission tomography measures of amyloid beta and tau pathologies with longitudinal subjective complaints and memory among 91 cognitively normal Baltimore Longitudinal Study of Aging participants using linear mixed effects models. Subjective complaints and memory performance were assessed with the Cognitive Failures Questionnaire and the California Verbal Learning Test, respectively.

Results: Greater parahippocampal tau, independent of amyloid, was associated with higher subjective complaints (estimate = 0.25, standard error [SE] = 0.1, P = $0.015$ ), while greater entorhinal tau corresponded to an attenuated increase in complaints over time (estimate = -0.06, SE = 0.03, P = $0.047$ ). Hippocampal tau was associated with steeper memory decline (estimate = -0.03, SE = 0.01, P = $0.040$ ).

Conclusion: Subjective cognitive complaints may be a reflection of early cerebral tau pathology in cognitively normal individuals.

Highlights: Greater parahippocampal tau was linked with higher subjective cognitive complaints.Entorhinal tau was associated with slower increases in cognitive complaints over time.Subjective complaints may reflect early amyloid and tau in cognitively normal adults.

Abstract Image

查看原文本刊更多论文

阿尔茨海默病的神经病理学和主观认知主诉的纵向变化。

主观上的认知抱怨往往先于认知表现的客观测量下降。在认知正常的个体中，早期阿尔茨海默病（AD）神经病理学与主观认知主诉的关联可能比与神经心理测试的关联更早被发现。方法：在91名认知正常的巴尔的摩老年纵向研究参与者中，我们使用线性混合效应模型检验了正电子发射断层扫描测量的β淀粉样蛋白和tau病理与纵向主观抱怨和记忆的独立关联。主观抱怨和记忆表现分别用认知失败问卷和加州语言学习测验进行评估。结果：与淀粉样蛋白无关的海马旁tau蛋白含量较高与较高的主观主诉相关（估计值= 0.25，标准误差[SE] = 0.1, P = 0.015），而随着时间的推移，较高的嗅内tau蛋白含量与主诉的增加减弱相关（估计值= -0.06,SE = 0.03, P = 0.047）。海马tau与更急剧的记忆衰退相关（估计值= -0.03,SE = 0.01, P = 0.040）。结论：主观认知抱怨可能是认知正常个体早期脑tau病理的一种反映。重点：海马旁tau蛋白的增加与较高的主观认知抱怨有关。随着时间的推移，内嗅tau蛋白与认知疾病的缓慢增长有关。主观主诉可能反映认知正常成人早期的淀粉样蛋白和tau蛋白。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.